Literature DB >> 26181836

A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?

Shinichiro Takao1, Kosuke Tanaka1, Masayuki Miyazaki1, Masatake Tanaka1, Tomoko Ohashi1, Masaki Kato1, Kazuhiro Kotoh2, Shinichi Aishima3, Ryoichi Takayanagi1.   

Abstract

Immunoglobulin light chain-associated (AL) amyloidosis is a multisystemic disorder characterized by extracellular deposition of immunoglobulin light chain produced by a proliferative plasma cell clone. Although the liver is the major organ involved in AL amyloidosis, hepatic involvement is often clinically asymptomatic and severe intrahepatic cholestasis as the primary manifestation of the disease is rare. A 60-year-old man with severe jaundice, massive ascites and highly elevated alkaline phosphatase was diagnosed with AL amyloidosis by a transjugular liver biopsy. He had undergone a yearly medical check that showed no abnormalities except for mild elevation of serum γ-glutamyltransferase at 1 year before admission. Owing to his poor condition and rapidly progressive liver and renal dysfunction, neither stem cell transplantation nor a combination of chemotherapeutic agents could be applied, and he died 1.5 months after admission. An autopsy revealed amyloid deposition in the systemic organs, and there was no evidence of multiple myeloma. Continuous elevation of γ-glutamyltransferase may be a useful marker for early diagnosis of fatal hepatic amyloidosis.

Entities:  

Keywords:  Alkaline phosphatase; Amyloidosis; Light chain; Liver failure; γ-Glutamyltransferase

Year:  2013        PMID: 26181836     DOI: 10.1007/s12328-013-0406-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  15 in total

1.  Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.

Authors:  César Samanez; Abel Domingo; M Teresa Cibeira; Rosa Miquel; Manel Soler; Joan Bladé
Journal:  Eur J Haematol       Date:  2006-01       Impact factor: 2.997

2.  Liver involvement with rapidly progressive course in light chain (AL) amyloidosis: distinguishing features at presentation. Experience of a single center.

Authors:  L Econimo; G Jeannin; L Biasi; G Mazzola; M Mendeni; K Presteni; G Gregorini
Journal:  Amyloid       Date:  2011-06       Impact factor: 7.141

Review 3.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  "Isolated" elevation of alkaline phosphatase: significance in hospitalized patients.

Authors:  D Lieberman; D Phillips
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

5.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

6.  Cholestasis and liver failure with lambda-AL amyloidosis.

Authors:  F Konikoff; C Mor; S Stern; M Shaklai; J Halevy; E Theodor
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

7.  Hepatic amyloidosis with light chain deposition disease. A rare association.

Authors:  M A Casiraghi; A De Paoli; A Assi; G Palladini; M T Lavazza; A Beretta; G Gualdoni; R Beretta
Journal:  Dig Liver Dis       Date:  2000-12       Impact factor: 4.088

Review 8.  Primary amyloidosis and severe intrahepatic cholestatic jaundice.

Authors:  R A Peters; G Koukoulis; A Gimson; B Portmann; D Westaby; R Williams
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

Review 9.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

10.  Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.

Authors:  M A Gertz; R A Kyle
Journal:  Am J Med       Date:  1988-07       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.